Metabolic oligosaccharide engineering: Implications for selectin-mediated adhesion and leukocyte extravasation

Ruben T. Almaraz, Mohit P. Mathew, Elaine Tan, Kevin J Yarema

Research output: Contribution to journalArticle

Abstract

Metabolic oligosaccharide engineering is an emerging technology wherein non-natural monosaccharide analogs are exogenously supplied to living cells and are biosynthetically incorporated into cell surface glycans. A recently reported application of this methodology employs fluorinated analogs of ManNAc, GlcNAc, and GalNAc to modulate selectin-mediated adhesion associated with leukocyte extravasation and cancer cell metastasis. This monograph outlines possible mechanisms underlying the altered adhesion observed in analog-treated cells; these range from the most straightforward explanation (e.g., structural changes to the selectin ligands ablate interaction with their receptors) to the alternative mechanism where the analogs inhibit or otherwise perturb ligand production to more indirect mechanisms (e.g., changes to the biophysical properties of the selectin binding partner, the nanoenviroment of the binding partners, or the entire cell surface).

Original languageEnglish (US)
Pages (from-to)806-815
Number of pages10
JournalAnnals of Biomedical Engineering
Volume40
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Oligosaccharides
Adhesion
Cells
Ligands
Selectins

Keywords

  • Biomechanical and biophysical properties of the glycocalyx
  • GalNAc
  • GlcNAc
  • Glycan engineering
  • ManNAc
  • Neu5Ac analog

ASJC Scopus subject areas

  • Biomedical Engineering

Cite this

Metabolic oligosaccharide engineering : Implications for selectin-mediated adhesion and leukocyte extravasation. / Almaraz, Ruben T.; Mathew, Mohit P.; Tan, Elaine; Yarema, Kevin J.

In: Annals of Biomedical Engineering, Vol. 40, No. 4, 04.2012, p. 806-815.

Research output: Contribution to journalArticle

@article{e64b54fdc1274cf880820456ae5d80e7,
title = "Metabolic oligosaccharide engineering: Implications for selectin-mediated adhesion and leukocyte extravasation",
abstract = "Metabolic oligosaccharide engineering is an emerging technology wherein non-natural monosaccharide analogs are exogenously supplied to living cells and are biosynthetically incorporated into cell surface glycans. A recently reported application of this methodology employs fluorinated analogs of ManNAc, GlcNAc, and GalNAc to modulate selectin-mediated adhesion associated with leukocyte extravasation and cancer cell metastasis. This monograph outlines possible mechanisms underlying the altered adhesion observed in analog-treated cells; these range from the most straightforward explanation (e.g., structural changes to the selectin ligands ablate interaction with their receptors) to the alternative mechanism where the analogs inhibit or otherwise perturb ligand production to more indirect mechanisms (e.g., changes to the biophysical properties of the selectin binding partner, the nanoenviroment of the binding partners, or the entire cell surface).",
keywords = "Biomechanical and biophysical properties of the glycocalyx, GalNAc, GlcNAc, Glycan engineering, ManNAc, Neu5Ac analog",
author = "Almaraz, {Ruben T.} and Mathew, {Mohit P.} and Elaine Tan and Yarema, {Kevin J}",
year = "2012",
month = "4",
doi = "10.1007/s10439-011-0450-y",
language = "English (US)",
volume = "40",
pages = "806--815",
journal = "Annals of Biomedical Engineering",
issn = "0090-6964",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Metabolic oligosaccharide engineering

T2 - Implications for selectin-mediated adhesion and leukocyte extravasation

AU - Almaraz, Ruben T.

AU - Mathew, Mohit P.

AU - Tan, Elaine

AU - Yarema, Kevin J

PY - 2012/4

Y1 - 2012/4

N2 - Metabolic oligosaccharide engineering is an emerging technology wherein non-natural monosaccharide analogs are exogenously supplied to living cells and are biosynthetically incorporated into cell surface glycans. A recently reported application of this methodology employs fluorinated analogs of ManNAc, GlcNAc, and GalNAc to modulate selectin-mediated adhesion associated with leukocyte extravasation and cancer cell metastasis. This monograph outlines possible mechanisms underlying the altered adhesion observed in analog-treated cells; these range from the most straightforward explanation (e.g., structural changes to the selectin ligands ablate interaction with their receptors) to the alternative mechanism where the analogs inhibit or otherwise perturb ligand production to more indirect mechanisms (e.g., changes to the biophysical properties of the selectin binding partner, the nanoenviroment of the binding partners, or the entire cell surface).

AB - Metabolic oligosaccharide engineering is an emerging technology wherein non-natural monosaccharide analogs are exogenously supplied to living cells and are biosynthetically incorporated into cell surface glycans. A recently reported application of this methodology employs fluorinated analogs of ManNAc, GlcNAc, and GalNAc to modulate selectin-mediated adhesion associated with leukocyte extravasation and cancer cell metastasis. This monograph outlines possible mechanisms underlying the altered adhesion observed in analog-treated cells; these range from the most straightforward explanation (e.g., structural changes to the selectin ligands ablate interaction with their receptors) to the alternative mechanism where the analogs inhibit or otherwise perturb ligand production to more indirect mechanisms (e.g., changes to the biophysical properties of the selectin binding partner, the nanoenviroment of the binding partners, or the entire cell surface).

KW - Biomechanical and biophysical properties of the glycocalyx

KW - GalNAc

KW - GlcNAc

KW - Glycan engineering

KW - ManNAc

KW - Neu5Ac analog

UR - http://www.scopus.com/inward/record.url?scp=84862115673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862115673&partnerID=8YFLogxK

U2 - 10.1007/s10439-011-0450-y

DO - 10.1007/s10439-011-0450-y

M3 - Article

C2 - 22037949

AN - SCOPUS:84862115673

VL - 40

SP - 806

EP - 815

JO - Annals of Biomedical Engineering

JF - Annals of Biomedical Engineering

SN - 0090-6964

IS - 4

ER -